SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Drug Development
AbbVie, Biohaven, Teva and Satsuma Tackle Migraine at AHS
The annual meeting of the American Headache Society (AHS) is being held in Denver, Colorado from June 9-12. Here’s a look at just some of the wide-ranging research being presented.
June 9, 2022
 · 
4 min read
 · 
Mark Terry
Drug Development
Clinical Catch-Up: NIH’s COVID-19 Trial and All About ASCO
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
June 3, 2022
 · 
13 min read
 · 
Mark Terry
Drug Development
J&J and BMS Drugs Reduce COVID-19 Deaths in Moderate-to-Severe Population
Bristol Myers Squibb’s Orencia and Johnson & Johnson’s Remicade improved survival rates for people hospitalized with COVID-19 according to a new report by the National Institutes of Health.
June 2, 2022
 · 
3 min read
 · 
Mark Terry
Flagship CEO Noubar Afeyan/The Boston Globe/Getty
Business
Flagship’s Tessera Wins Services of Ex-AbbVie Exec Severino
Tessera Therapeutics announced Thursday that ex-AbbVie executive Michael Severino, M.D. will take the helm of the young biotech.
June 2, 2022
 · 
2 min read
 · 
Paul Besabella
SKYRIZI is the new option for psoriatic arthritis.
Business
Report Predicts AbbVie Could Become Top-Selling Pharma Company by 2028
The report suggests that AbbVie’s sales will be approximately $65.7 billion within the next six years, with Roche right behind at $65 billion.
June 1, 2022
 · 
2 min read
 · 
Alex Keown
From left: Nia Phipps and Lavery Hughes, recipient
Business
AbbVie is Enabling Students Diagnosed with Immunological Diseases to Shine
The AbbVie Immunology Scholarship provides financial support to students living with chronic, immune-mediated diseases who are pursuing higher education in the United States.
June 1, 2022
 · 
4 min read
 · 
Alex Keown
Michael Vi/Getty Images, Mark Wildgust_Janssen Bio
Drug Development
Janssen Presents New Data that could Set Anti-Inflammatory Drug Tremfya Apart
Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.
May 19, 2022
 · 
2 min read
 · 
Alex Keown
Kent Sievers/Shutterstock
Business
Warren Buffet’s Latest Moves Reflect Biopharma Market Woes
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
May 18, 2022
 · 
2 min read
 · 
Alex Keown
Business
AbbVie, AstraZeneca See Value in what Cugene, Proteros Have to Offer
Cugene and AbbVie came together on autoimmune diseases and cancer, while Proteros and AstraZeneca expanded their collaboration on epigenetic cancer drugs.
May 16, 2022
 · 
3 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Job Trends
AbbVie to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
 · 
1 min read
BioMidwest
AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
February 27, 2023
 · 
25 min read
Policy
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn’s Disease
February 27, 2023
 · 
18 min read
BioMidwest
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
February 23, 2023
 · 
4 min read
Business
AbbVie Declares Quarterly Dividend - February 16, 2023
February 16, 2023
 · 
1 min read
Business
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
February 9, 2023
 · 
27 min read
Job Trends
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
January 25, 2023
 · 
3 min read
Job Trends
Childhood Cancer Patients and Their Families Find a Home Away From Home
January 24, 2023
 · 
5 min read
Business
BioMed X and AbbVie Extend Research Collaboration in the USBioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie.
January 16, 2023
 · 
4 min read
Business
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
January 10, 2023
 · 
5 min read
Load More